The Laboratory for Molecular Neuro-Oncology at the University of Zurich is seeking a highly motivated postdoctoral researcher to join an ERC-funded project developing next-generation chimeric antigen receptor (CAR) immune cell therapies against malignant brain tumors.
What we Offer:
- A fully funded postdoctoral position within a prestigious ERC-funded project
- Access to cutting-edge engineering, screening, and profiling platforms
- An interdisciplinary and collaborative environment at the forefront of cancer, immunology, and neuroscience
- Opportunities to engage with translational and clinical research
- Mentorship from leaders in the field and full support for a successful career in academia or in the entrepreneurial space
Background:
Malignant primary brain tumors remain among the most challenging tumor types to treat. Cancer immunotherapies hold revolutionary potential, and our group has pioneered multiple immunotherapeutic approaches against brain cancer, including tumor-targeted cytokine therapies (Weiss et al., Science Translational Medicine 2020; Look et al., Science Translational Medicine 2023) and engineered immune cell therapies (Sun et al., Science Translational Medicine 2025), leveraging sophisticated in vitro and in vivo models and cutting-edge technologies. Our team also has a strong track record of translating preclinical innovation into patient care.
Project Description:
In this ERC-funded project, the successful candidate will develop the next generation of immune cell therapies. Building on our established ex vivo and in vivo engineering platforms, sophisticated single-cell and spatial technologies, disease models, and patient samples, the project aims to further develop multifunctional, multi-immune-cell strategies for the treatment of malignant brain tumors.
